Research programme: hematopoietic stem cell therapies - Garuda Therapeutics
Alternative Names: Research programme: HSC therapies - Garuda TherapeuticsLatest Information Update: 20 Jan 2022
At a glance
- Originator Garuda Therapeutics
- Class Antineoplastics; Haematopoietic stem cells therapies; Immunotherapies
- Mechanism of Action Cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Research Beta-thalassaemia; Bone marrow transplant rejection; Haematological malignancies; Sickle cell anaemia